P&K SKIN RESEARCH CENTER CO., LTD. P&K Skin Research Center Co., Ltd. Share Price
Equities
A347740
KR7347740003
Business Support Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,840 KRW | -2.24% |
|
+0.18% | +15.45% |
| Sales 2022 | 17.96B 13.05M 1.09B | Sales 2023 | 14.84B 10.79M 899M | Capitalization | 73.83B 53.67M 4.47B |
|---|---|---|---|---|---|
| Net income 2022 | 7.13B 5.18M 432M | Net income 2023 | 4.81B 3.5M 292M | EV / Sales 2022 | 1.91 x |
| Net cash position 2022 | 56.72B 41.24M 3.44B | Net cash position 2023 | 44.02B 32M 2.67B | EV / Sales 2023 | 2.01 x |
| P/E ratio 2022 |
12.7
x | P/E ratio 2023 |
15.3
x | Employees | - |
| Yield 2022 |
1.15% | Yield 2023 |
1.22% | Free-Float | 40.59% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.24% | ||
| 1 week | +0.18% | ||
| Current month | -1.90% | ||
| 1 month | -3.89% | ||
| 3 months | +15.68% | ||
| 6 months | +24.56% | ||
| Current year | +15.45% |
1 week
2 810.00
2 945.00
1 month
2 710.003 145.00
Current year
2 365.003 290.00
1 year
2 225.003 655.00
3 years
2 225.008 340.00
5 years
2 225.008 340.00
10 years
2 225.008 340.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hae-Kwang Lee
CEO | Chief Executive Officer | 60 | - |
Jin-Oh Park
CEO | Chief Executive Officer | 52 | - |
Ho-Woo Nam
DFI | Director of Finance/CFO | 50 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jin-Oh Park
CEO | Chief Executive Officer | 52 | - |
Hae-Kwang Lee
CEO | Chief Executive Officer | 60 | - |
Ho-Woo Nam
DFI | Director of Finance/CFO | 50 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 2,840 | -2.24% | 61,139 |
| 25/24/25 | 2,905 | -0.85% | 55,485 |
| 24/24/24 | 2,930 | +2.09% | 127,485 |
| 23/24/23 | 2,870 | 0.00% | 63,900 |
| 22/24/22 | 2,870 | +1.23% | 55,629 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
P&K Skin Research Center Co Ltd a Korea-based company mainly engaged in the business of skin human application testing. The Company provides services such as human application testing, safety tests, cosmetic efficacy tests, cosmeceuticals tests, health food tests, sensory tests, and in vitro tests. In addition, the Company perform scientific evaluations of efficacy for products applied to human skin to provide information about the products and technical support.
Sector
Business Support Services
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +15.45% | 61.92M | |
| +14.61% | 17.2B | |
| 0.00% | 6.8B | |
| -12.39% | 2.88B | |
| -11.15% | 2.72B | |
| -31.21% | 1.74B | |
| +5.00% | 1.25B | |
| -7.31% | 1.06B | |
| -6.67% | 870M | |
| -4.08% | 794M |
- Stock Market
- Equities
- A347740 Stock
